A diazo-positive fraction of serum bilirubin that is irreversibly bound to albumin has been shown to accumulate in serum ofpatients with cholestasis. In the present study, a cholestatic animal model was used to determine the chemical nature of the bilirubin species involved in its formation. The data indicate that conjugated bilirubin is the precursor of "albumin-bound bilirubin" and that the presence or absence of light does not affect its formation. An albumin-bound bilirubincomplex indistinguishable from the complex detected in cholestatic sera from patients or in bile duct-ligated Sprague-Dawley rats can be formed in vitro in sera enriched in conjugated bilirubin at 370C, pH 7.4.
Introduction
The serum levels of unconjugated bilirubin as well as bilirubin monoglucuronide and diglucuronide are increased in patients with cholestasis. In normal sera, these tetrapyrroles exist bound to albumin through reversible ionic bonds (1, 2) . Recently, a direct-reacting, diazo-positive bilirubin compound that is irreversibly bound to albumin was detected and quantified in sera of patients with cholestatic diseases (3, 4) . A similar com-pound was previously described by both Nosslin (5) and Kuenzle et al. (6) but their observations were overlooked until recently.
This bilirubin species, albumin-bound bilirubin, is detected as a significant fraction of total serum bilirubin in jaundiced patients with a variety of hepatobiliary diseases, but is not detected in healthy volunteers, in neonates with physiological jaundice, or in patients with hemolysis or Gilbert's disease (4) . Our findings suggested that conjugates of bilirubin may be the source of this compound. In addition, during recovery from jaundice, albumin-bound bilirubin persists and eventually becomes the predominant fraction of total bilirubin in serum. This phenomenon probably occurs because of the tight binding to albumin so that the turnover of albumin then determines the compound's half-life in serum; this could explain the wellknown delay in resolution of jaundice in some patients who have recovered normal hepatobiliary function (4) .
In the present study, an animal model for albumin-bound bilirubin was used to investigate the chemical nature of the bilirubin species and the site of formation of albumin-bound bilirubin. Bile duct-ligated Sprague-Dawley rats and homozygous Gunn rats were chosen for these experiments. In the Sprague-Dawley rats, the level of both unconjugated and conjugated bilirubin would increase in serum, while in the Gunn rats, only unconjugated bilirubin would increase. Additionally, the effect of an infusion of unconjugated bilirubin and phototherapy on the formation of albumin-bound bilirubin was compared in the two groups of animals.
Animals. Male Sprague-Dawley rats (200-250 g, Charles River Laboratories, Wilmington, MA) and male, homozygous Gunn rats (200-300 g, Blue-Spruce Farms, Albany, NY) were housed in temperatureand humidity controlled rooms and had free access to water and Purina rat chow (Ralston Purina Co., Chicago, IL). Animals were not starved before surgery.
Surgical procedures. Under ether/ketamine anesthesia, the bile duct was cut between double ligatures above the entrance of the pancreatic ducts. After surgery, the animals were housed in individual cages. In the initial postoperative phase (1-2 d), the animals lost up to 10% of their body weight before resuming weight gain. Blood samples for determination ofalbumin-bound bilirubin and total bilirubin were obtained from the tail vein at 24-48-h intervals. The serum was separated and analyzed immediately or frozen at -20'C and analyzed within 24 h.
Preparation and infusion ofconjugated and unconjugated bilirubin
Unconjugated bilirubin. 25 mg (42.7 Mmol) of bilirubin was dissolved in 0.20 M NaOH, added to enough 25% human serum albumin to give a final concentration of 5% human serum albumin and then neutralized to pH 7.5 with dilute HCI to yield an isotonic solution containing 1.25 mg/ml of bilirubin. On high pressure liquid chromatography (7) , extracts of this material chromatographed as unconjugated bilirubin IX-a. Infusions of this material were made into the jugular vein of rats with a size 23 butterfly needle at the rate of 2-3 ml/h (4-6 Mmol of bilirubin/ h) using a Harvard infusion pump (Harvard Apparatus, Dover, MA). Conjugated bilirubin. Bile, containing high concentrations of conjugated bilirubin, was collected on ice in the dark via a polyethylene bile duct-cannula (PE-50 tubing, Clay-Adams, Parsippany, NJ) from Sprague-Dawley rats that were infused with 4-6 Mmol of bilirubin. Saccharo-1-4-lactone (1 mM) was added and samples frozen immediately and used within 24-48 h. These samples contained 100-150 mg/100 ml ofbilirubin conjugates. High pressure liquid chromatographic analysis of these enriched bile samples (7) revealed no significant unconjugated bilirubin and these samples contained 65% diglucuronide and 35% monoglucuronide. These bile samples were used as a source for bilirubin conjugates and in experiments requiring infusion of conjugated bilirubin, 2-3 ml of enriched bile, containing 3-6 ,gmol of bilirubin were infused at 2.5 ml/h. Purified conjugates of bilirubin were prepared from bile as outlined by Berk et al. (8) and used in some in vitro incubations. These samples contained primarily bilirubin monoglucuronide and diglucuronide by thin-layer chromatography (9) .
Phototherapy. Gunn rats were shaved and exposed to a flux of 20 ,MW/cm2 per nm, provided by banked Daylite fluorescent lamps (Sylvania Electronic Products & Services, Williamsport, PA) kept at 24 in. from skin surface for two 48-h periods separated by a 24-h recovery period.
In vitro incubation ofbilirubin samples with human serum. Samples ofunconjugated bilirubin (19-36 mg/100 ml), bile enriched with bilirubin conjugates and purified conjugates (28-60 mg/100 ml) were incubated for 24 h with normal fasting human serum at 370C, pH 7.4 under nitrogen in sealed tubes containing penicillin/streptomycin (100 U/100 Mg per ml). This bilirubin/serum mixture was also analyzed immediately after mixing or after being maintained at 250C. Measurement ofalbumin-bound bilirubin. Albumin-bound bilirubin was measured chemically in samples by a method developed by Seligson, H., D. Seligson, and T.-W. Wu (submitted for publication). Briefly, cholestatic serum samples (150 Ml), containing bilirubin, its conjugates, and albumin-bound bilirubin, were diazotized according to the Doumas et al. (10) modification of the Jendrassik-Grof diazo reaction. Blanks were treated identically except for the omission of NaNO2. After addition of the alkaline tartarate reagent, the diazotized serum was added to 50 mg of prepared (chloride free) anion-exchange resin, shaken for 25 min in the dark, and then filtered twice to remove azoderivatives of the bilirubin fractions that were not bound covalently to albumin. Azoderivatives of albumin-bound bilirubin were not retained by this resin. The effluent from the ion-exchange resin was measured spectrophotometrically at 660 nm and albumin-bound bilirubin was quantified after subtracting the absorbance of the blank. Validation of the photometric method was obtained by comparison of values of albumin-bound bilirubin obtained by this method on 54 jaundiced serum samples, with values obtained by the high pressure liquid chromatographic method of Lauffet al. 
Results
Negligible amounts of albumin-bound bilirubin were detected in conjugated bilirubin standards (total bilirubin, 21-65 mg/ 100 ml; albumin-bound bilirubin, 0.5-1.1%) or in conjugated bilirubin derived from rat bile (total bilirubin, 31-208 mg/100 ml; albumin-bound bilirubin 0-0.3%). Similarly, as shown in Table I , negligible amounts of albumin-bound bilirubin were detected in reaction mixtures containing unconjugated bilirubin (513±87 gmol/liter) in human serum or conjugated bilirubin (584±102 ,mol/liter) in sera which were assayed immediately (0.11±0.06%, n = 5; 1.03±1%, n = 7, respectively, expressed as percentage of total bilirubin).
Formation of albumin-bound bilirubin
In vivoformation in cholestatic rats. Total serum bilirubin rose to similar peak levels of 16.0±3 mg/100 ml and 16.8±3.2 mg/ 100 ml within 24-72 h after bile duct-ligation in Sprague-Dawley and Gunn rats, respectively ( Fig. 1 A) . The initial serum bilirubin levels were significantly higher in Gunn rats and after ligation of bile ducts, the serum values increased more rapidly than in Sprague-Dawley rats. However, in both experimental groups, this initial rise was followed by a slow decline in total serum bilirubin. This phenomenon has been described previously in the bile duct-ligated rat model (12) and presumably is a result of an enhanced efficiency of nonhepatic routes for bilirubin excretion. In Sprague-Dawley rats, albumin-bound bilirubin was detected within 24 h of bile duct-ligation (0.73±0.27 mg/100 ml; 12.5±4.6 Mmol/liter of bilirubin) and this level increased slowly during the experimental period to account for 40-45% of total serum bilirubin on the 10th d (3.8±0.31 mg/100 ml). In contrast, albumin-bound bilirubin was not detected in sig- Indicated values are means±SD. Comparison was made between albumin-bound bilirubin formed on incubation of conjugated bilirubin with albumin at 370C and (a) incubation at 250C (*P < 0.02) and (b) incubation of unconjugated bilirubin with albumin at 370C (fP < 0.001).
nificant amounts in sera of bile duct-ligated Gunn rats at any point during the experimental period. Total serum bilirubin was significantly increased in both bile duct-ligated Sprague-Dawley and Gunn rats after infusion of 2 gmol/100 g body wt i.v. of bilirubin over 60-90 min (Fig.   1 B) . In Sprague-Dawley rats, this was associated with a significant enhancement in the amount ofalbumin-bound bilirubin detected 24 h after infusion (2.84±0.7 mg/100 ml, which was significantly greater than that found in Sprague-Dawley rats after bile duct-ligation alone, P < 0.001). Again, virtually no albumin-bound bilirubin was detected in sera of the bile ductligated Gunn rats infused with bilirubin and treated in the same manner.
When bile samples enriched in bilirubin conjugates (containing 1 mM saccharo-1 -4-lactone) were infused into Sprague-Dawley rats, significantly increased amounts of albumin-bound bilirubin were detected at 24 h (2.8±0.4 mg/100 ml) (Fig. 2) . Albumin-bound bilirubin was also readily detected in sera of bile duct-ligated Gunn rats (1.3±0.5 mg/100 ml at 24 h). This experiment represented the only experimental condition in which albumin-bound bilirubin was detected in cholestatic Gunn rats.
To study the effect of light on albumin-bound bilirubin formation, Sprague-Dawley rats were kept in complete dark after bile duct-ligation ( Fig. 3, left) and compared with rats kept in a normal, 12-h alternating light-dark cycle after surgery. There was no significant difference, either in total bilirubin or in albumin-bound bilirubin levels in the two groups. In Gunn rats (Fig. 3, right) , total bilirubin rose after bile duct-ligation and declined with phototherapy. However, there was no significant albumin-bound bilirubin formation. In vitro formation. In vitro incubation of conjugated but not unconjugated bilirubin at 370C, pH 7.4 for 24 h resulted in the tight binding of 3-6% of bilirubin to albumin (Table I) . At room temperature, this in vitro formation ofalbumin-boundbilirubin-like material was significantly decreased (2.7±0.6% of total bilirubin, P < 0.02).
Discussion
The present study confirms, in an animal model, our earlier observation in patients that albumin-bound bilirubin is detected in serum in the presence of conjugated but not unconjugated hyperbilirubinemia (4) . The ready formation ofalbumin-bound bilirubin in cholestatic Sprague-Dawley rats (with an intact bilirubin conjugating mechanism) and Gunn rats infused with conjugated bilirubin indicates that bilirubin conjugates are the direct precursors of albumin-bound bilirubin formation.
Covalent linkage oflight-irradiated bilirubin to albumin has been reported to occur both in vivo and in vitro (13) . However, our results indicate that exposure to phototherapy does not result in formation of detectable amounts of albumin-bound bilirubin. In this study no attempt was made to measure bilirubin photoisomers which accumulate in serum of Gunn rats after phototherapy (14) . Their formation and excretion, into urine and the intestine, may be partly responsible for the fall in total serum bilirubin seen after phototherapy. Detection of albuminbound-bilirubin-like substance(s) on incubating conjugated bilirubin with albumin indicates that a tightly bound bilirubinalbumin complex can be formed in vitro by a temperature-dependent, nonenzymatic mechanism. This compound is indistinguishable from albumin-bound bilirubin by the ion-exchange resin-filtration method used in this study that selectively measures azoderivatives of bilirubin coupled irreversibly to albumin. Preliminary evidence obtained in this laboratory from sodium dodecyl sulfate-polyacrylamide electrophoresis of albumin-bound 3H-bilirubin samples further supports the similarity ofthe compounds formed in vivo and in vitro. 3H-bilirubin counts are predominantly associated with the albumin band in both samples ofalbumin-bound bilirubin obtained from in vivo (bile duct-ligated rat) sources and those obtained on incubation of 3H-conjugated bilirubin with normal serum in vitro.
Further studies are required to determine if the in vivo formation of albumin-bound bilirubin occurs in the liver or in peripheral circulation; ifthe albumin-bound bilirubin compound formed in vitro is the same as that formed in vivo; and to determine the overall pathophysiological significance of this unique, tight binding of a conjugated bilirubin species to albumin.
